TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06787794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-assisted hypnosis
Description: The VRH intervention consists of 6 interventional sessions. Every session, first, participants receive hypnotic induction and go through a deepening phase using a hypnotic script and a VR environment designed based on input from individuals suffering from chronic itch. To this end, participants are instructed to close their eyes while they will continue to listen to the recorded hypnotic script developed based on general hypnotic principles as amongst others described by Yapko (2013). Direct antipruritic suggestions are used such as your skin will feel so soft, relaxed and cool, it is fully at ease. After these standardized suggestions, the participants will be alerted again. Home exercises (ca 5 min/day) include guided self-hypnosis records with direct antipruritic suggestions comparable to the ones they listen to during the intervention at location.
Study: NCT06786962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality Hypnosis
Description: The experimental group of 22 participants consists of a hypnosis intervention using a virtual reality device (HypnoVR®).~Participants are seated in a quiet area of the unit:~They choose a visual scenario from among 3 proposals, guaranteeing the conditions of a restorative environment. During each session, the same script (support mode) is spoken and the same music (serenity program with soothing tones) is associated with the script. Each participant is fitted with a virtual reality mask and a headset with active noise reduction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm (SEQ):
Description: Restoration time~Participants are seated in a quiet area of the unit. The control group of 21 participants consists of a break with the following instructions and suggestions:~Take advantage of this break, this time just for you, to recharge your batteries. Sit in this armchair and I suggest you think of something pleasant and comfortable.
Study: NCT06786494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tart Cherry Juice
Description: Individuals will be asked to consume 240 mL (i.e., 8 ounces) at approximately 5 pm and 240 mL (i.e., 8 ounces) of tart cherry juice at approximately 1 hour before bedtime for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: Individuals will be asked to consume 240 mL (i.e., 8 ounces) at approximately 5 pm and 240 mL (i.e., 8 ounces) of placebo juice at approximately 1 hour before bedtime for 4 weeks.
Study: NCT06095258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine treatment
Description: About four to six Chinese medicine practitioners with five to twenty years of clinical work experience will be responsible for patient diagnosis and prescription treatment, and use a uniformly designed data collection form to record the patient's medical history, clinical symptoms and signs, tongue and pulse conditions, and other information. Patients in the treatment group will receive individualized Chinese medicine treatment prescriptions. Patients in the control group received conventional Western medicine treatment, and about 3 to four Western medicine practitioners with five to twenty years of work experience will be responsible for the conventional medicine prescription. The treatment of the two groups will last for four weeks, and the patients will be followed up for four weeks after the treatment. A patient diary will be provided to all participants for recording the drug compliance and any adverse event during the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Western medicine treatment
Description: Western medicine doctors will mainly use symptomatic drugs to treat long COVID. For example, cough medicine (such as codeine), bronchodilators (such as ventolin), expectorants (such as fluimucil) and so on are used to treat cough, shortness of breath, or other respiratory symptoms. Non-steroidal anti-inflammatory painkillers (such as panadol) are often used for treating headaches, and sedative-hypnotic drugs (such as stilnox) are often used to treat insomnia.
Study: NCT05859165

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutren Diabetes
Description: Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin Diabetes
Description: Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day
Study: NCT05569148

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Faricimab PFS Configuration
Description: Participants will receive a single intravitreal (IVT) injection of the 6-milligram (mg) faricimab dose formulation delivered via prefilled syringe (PFS) with a co-packaged injection filter needle.
Study: NCT06328283

Intervention type: OTHER
Intervention: measure of Glutamine synthetase and BCLFAF1
Description: compare Glutamine synthetase and BCLFAF1 in cases and controls

Intervention type: OTHER
Intervention: measure of Glutamine synthetase and BCLFAF1
Description: compare Glutamine synthetase and BCLFAF1 in cases and controls
Study: NCT05480722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Subjects will consume a low salt diet for 1 week and a high salt diet for 1 week to determine sodium sensitivity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: Subjects will undergo MRI with a hypertonic saline infusion with and without NKCC2 antagonism (furosemide)
Study: NCT06288282

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention will be used.
Study: NCT05861895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF158K1 /Arm 2 mg/m²
Description: Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF158K1 /Arm 6 mg/m²
Description: Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF158K1 /Arm 15 mg/m²
Description: Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF158K1 /Arm 30 mg/m²
Description: Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF158K1 /Arm 45 mg/m²
Description: Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF158K1 /Arm 60 mg/m²
Description: Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
Study: NCT06148155

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-RG2 PET Imaging
Description: Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RG2 in a single dose.
Study: NCT06785662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The budesonide nasal irrigation
Description: The participant in this group used a solution containing 1 milligram of budesonide mixed with 240 milliliters of normal saline in a squeeze bottle (Cleanoze®) for nasal irrigation. The procedure will be performed once daily while leaning slightly forward over a sink.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The budesonide nasal spray
Description: The participants in this group used a nasal spray containing 64 micrograms of budesonide per spray, with two sprays per nostril administered twice daily (morning and evening).
Study: NCT06786026

Intervention type: DRUG
Group type: OTHER
Intervention: bevacizumab
Description: bevacizumab

Intervention type: DRUG
Group type: OTHER
Intervention: QL1706
Description: Bispecific antibody (bsAB) targeting PD-1 and CLTA-4

Intervention type: DRUG
Group type: OTHER
Intervention: QL1706
Description: Bispecific antibody (bsAB) targeting PD-1 and CLTA-4

Intervention type: DRUG
Group type: OTHER
Intervention: Nab paclitaxel
Description: albumin-bound paclitaxel

Intervention type: DRUG
Group type: OTHER
Intervention: Nab paclitaxel
Description: albumin-bound paclitaxel
Study: NCT06783257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonorasan fumarate injection1
Description: 40 mg (20 mg bid, 6 hours apart, Day1) + 20 mg (Day2\&3, q24h), ivd, 30 min, administered for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonorasan fumarate injection2
Description: 40mg（Day1）+20mg（Day 2\&3），ivd，30min，q24h，administered for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole sodium for injection
Description: 80mg，iv，30±3min； Followed by 8 mg/h, ivd, 71.5 h
Study: NCT06787248

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: real-time fMRI sham-controlled neurofeedback training procedure
Description: real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 4.2 software (Brain Innovation, Maastricht, The Netherlands)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: real-time fMRI sham-controlled neurofeedback training procedure
Description: real-time fMRI neurofeedback training procedure running on the Turbo Brain voyager (TBV) 4.2 software (Brain Innovation, Maastricht, The Netherlands)
Study: NCT06786858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandMate
Description: HandMate device is used for 20 hours in 4 weeks. Device is then used in the home for 3 months at discretion of participant.
Study: NCT06787924

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen hydrolyzed peptides
Description: bovine collagen peptides

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Description: Starch placebo
Study: NCT06782919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk control training
Description: Four sessions of biofeedback trunk movement training, provided once per week.
Study: NCT06784219

Intervention type: DIAGNOSTIC_TEST
Intervention: Hindi version of self reported oral health questionnaire
Description: The original 8-item CDC/AAP questionnaire as well as other selected periodontal disease surveillance questions will be translated into Hindi through forward translation, backward translation, and expert committee process to reach a consensus and produce a prefinal version. The prefinal version questionnaire will be pilot tested on a sample of 20 patients to evaluate the overall comprehension by non-professionals. On the basis of responses and evaluation from the participants, the questionnaire will be further refined to build the final version. The final version of the questionnaire will be administered to patients seeking care from out-patient department of department of Periodontics at PGIDS, Rohtak. The participants will be required to fill the questionnaire by themselves prior to periodontal examination, without any help from others.
Study: NCT06783413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group (Laughter Yoga)
Description: Laughter yoga is a practice that includes physical laughing exercises and breathing techniques. Sessions will be conducted as group therapy with a trained guide. The intervention will be applied to evaluate changes in participants' fatigue, sleep quality and psychological well-being.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Participants in the control group will continue to receive their current standard of care and will not receive any additional interventions.
Study: NCT06784349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-APOC3
Description: Administered as per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-APOC3
Description: Administered as per the protocol
Study: NCT06294119

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Major Cardiac surgery
Description: From a clinical perspective, MANCAVA will especially target neuro-cardiovascular health and mood disorders such as depression
Study: NCT05110365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: The patient will be provided with mild to moderate resistance PNF pattern which is a type of Endurance training which decreases BP through a reduction in systemic vascular resistance(15).In a regimen as follow with the frequency of 3 days a week, a repetition of 3 sets for one hour and a total duration of 3 months(16). The PNF patterns will be diagonal 1 (D1) and diagonal 2 (D2) patterns. Both patterns are subdivided into: A) Moving into Flexion: the toes start flexed and ends extended. Ankle and foot start plantar flexed; everted and ends dorsiflexed inverted. Tibia starts externally rotated and ends internally rotated. Knee starts extended, and ends flexed. The hip starts extended, abducted, internally rotated and ends flexed, adducted, externally rotated.B) Moving into Extension: The start and end are reversed to D1 Moving into Flexion
Study: NCT05236855

Intervention type: DIAGNOSTIC_TEST
Intervention: Spectoscropy testing of urine specimen
Description: Urine samples will be independently tested by I R Spectroscopy and those results are to be compared with standard testing procedures for HPV
Study: NCT06784349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-APOC3
Description: Administered as per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-APOC3
Description: Administered as per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Administered as per the protocol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Administered as per the protocol
Study: NCT06786559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistive Device and health Education
Description: After discharge they will be assessed and followed by RA nurses through home visit and tele services for 2 months. The nurses will contact the patients periodically over telephone, and follow up their regular self-care activities, adjustment to devices, exercise and adaptive behavior.
Study: NCT06782737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietetic interventión with mediterranean diet
Description: Personalized dietary Mediterranean diet
Study: NCT06786715

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde intrarenal surgery using DISS
Description: Retrograde intrarenal surgery using Direct in scope suction for renal stone up to 3 cm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde intrarenal surgery using FANS
Description: Retrograde intrarenal surgery using Flexible and navigable suction for renal stone up to 3 cm
Study: NCT06788015

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrogen-infused water
Description: Water containing molecular hydrogen

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water containing no molecular hydrogen
Study: NCT06787456

Intervention type: DIAGNOSTIC_TEST
Intervention: EBV antibodies test
Description: ELISA test of VCA-IgA, EBNA1-IgA, EA-IgA, Zta-IgA, Rta-IgG and P85-Ab in nasopharyngeal brushing and plasma in plasma, saliva and nasopharyngeal brushing.

Intervention type: DIAGNOSTIC_TEST
Intervention: EBV DNA test
Description: quantitative polymerase chain reaction, methylation sequencing and target sequencing of EBV DNA in nasopharyngeal brushing, saliva and plasma.

Intervention type: OTHER
Intervention: epidemiological information survey
Description: epidemiological information survey including basic conditions, dietary and lifestyle habits, social, geographical, environmental, and other information.

Intervention type: OTHER
Intervention: Clinical examinations for high-risk participants
Description: nasopharyngoscopy, head and neck MRI.

Intervention type: OTHER
Intervention: EBV and human genetic sequencing
Description: EB virus and human genetic sequencing for plasma, etc.
Study: NCT04685421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.
Study: NCT05448144

Intervention type: OTHER
Intervention: Collect stool and blood samples from patients
Description: Collect stool and blood samples from patients

Intervention type: OTHER
Intervention: Collect stool and blood samples from patients
Description: Collect stool and blood samples from patients

Intervention type: OTHER
Intervention: Collect stool and blood samples from patients
Description: Collect stool and blood samples from patients
Study: NCT06783309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-103
Description: CNP-103 Drug Product is a lyophilized powder containing ≥1 μg of each individual recombinant protein comprising the CNP-103 Drug Substance per mg of nanoparticles, with each vial containing 100 mg of CNP-103.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-103
Description: CNP-103 Drug Product is a lyophilized powder containing ≥1 μg of each individual recombinant protein comprising the CNP-103 Drug Substance per mg of nanoparticles, with each vial containing 100 mg of CNP-103.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-103
Description: CNP-103 Drug Product is a lyophilized powder containing ≥1 μg of each individual recombinant protein comprising the CNP-103 Drug Substance per mg of nanoparticles, with each vial containing 100 mg of CNP-103.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-103
Description: CNP-103 Drug Product is a lyophilized powder containing ≥1 μg of each individual recombinant protein comprising the CNP-103 Drug Substance per mg of nanoparticles, with each vial containing 100 mg of CNP-103.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-103
Description: CNP-103 Drug Product is a lyophilized powder containing ≥1 μg of each individual recombinant protein comprising the CNP-103 Drug Substance per mg of nanoparticles, with each vial containing 100 mg of CNP-103.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-103
Description: CNP-103 Drug Product is a lyophilized powder containing ≥1 μg of each individual recombinant protein comprising the CNP-103 Drug Substance per mg of nanoparticles, with each vial containing 100 mg of CNP-103.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP-103
Description: CNP-103 Drug Product is a lyophilized powder containing ≥1 μg of each individual recombinant protein comprising the CNP-103 Drug Substance per mg of nanoparticles, with each vial containing 100 mg of CNP-103.
Study: NCT05006274

Intervention type: DEVICE
Intervention: Persona Trabecular Metal Tibia
Description: Total knee arthroplasty

Intervention type: DEVICE
Intervention: Persona Trabecular Metal Tibia
Description: Total knee arthroplasty

Intervention type: DEVICE
Intervention: Verasense technology
Description: Instrumented tibial trial component

Intervention type: DEVICE
Intervention: Verasense technology
Description: Instrumented tibial trial component

Intervention type: DEVICE
Intervention: MUVR
Description: Knee motion and gait sensing wearable device

Intervention type: DEVICE
Intervention: MUVR
Description: Knee motion and gait sensing wearable device
Study: NCT06517745

Intervention type: PROCEDURE
Intervention: Prone positioning
Description: Prone positioning sessions: at least one session per day proning duration: 2 hours at least per session
Study: NCT06118463

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of serum AUNIP expression
Description: The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of serum AUNIP expression
Description: The experiment is carried out according to the ELISA kit instructions, and the absorbance optic density (OD) value of the enzyme labeler at 450 nm is read. The protein concentration of AUNIP in the serum sample is calculated according to the standard curve.
Study: NCT06130020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing: Self
Description: This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing to themselves.
Study: NCT05881031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Initiation of NiPPV
Description: Initiation of NiPPV in the home environment through the utilization of an awake NiPPV titration, oximetries, and telemonitoring.
Study: NCT06130020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing: Other
Description: This intervention consists of a daily expressive writing exercise carried out for 14 consecutive days, for 15 minutes each day. Expressive writing involves asking participants to write about their deepest thoughts and feelings surrounding an emotional event. Participants in this condition will write as if they are writing/talking to someone they're close to.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Factual Writing
Description: This intervention consists of a daily factual writing exercise carried out for 14 consecutive days, for 15 minutes each day. Participants are asked to give a factual description of their day. This is a standard control for Expressive writing studies. Participants in this condition will be asked to direct their writing to themselves.
Study: NCT06529159

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HEAPE
Description: The stomach is filled with sodium chloride solution which is then treated with APC to activate it into an antibacterial solution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-HEAPE
Description: Plasma activated sodium chloride solution (prepared outside of the body) is administered into the patients stomach through an endoscope channel using a syringe.